Progress of immunotherapy in pediatric lymphocyte malignancies
10.3760/cma.j.issn.1673-4408.2021.09.010
- VernacularTitle:儿童淋巴细胞恶性肿瘤免疫治疗的研究进展
- Author:
Wenjie LI
1
;
Kejun HE
Author Information
1. 上海交通大学医学院附属新华医院儿血液肿瘤科 200092
- Keywords:
Pediatric leukemia;
Lymphoma;
Immunotherapy;
Side effects
- From:
International Journal of Pediatrics
2021;48(9):623-627
- CountryChina
- Language:Chinese
-
Abstract:
In the last half-century, the multi-cooperation of conventional therapies including chemotherapy, radiotherapy and bone marrow hematopoietic stem cell transplantation has saved a lot of children with lymphocyte malignancies, but the outcomes of relapsed and/or refractory diseases remain dismal.Thus, it is in urgent need of novel approaches to improve clinical efficiency.After decades of rapid development, immunotherapy has achieved remarkable results from the treatment of pediatric lymphocyte malignancies, especially chimeric antigen receptors T(CAR-T), bi-specific T cell engager(BiTE), and immune checkpoint blockader(ICB). However, a part of patients is still resistant to immunotherapy.The review will focus on CAR-T, BiTE and ICB to elucidate the pre-clinical studies and clinical trials that have been intensively conducted in pediatric leukemia and lymphoma, as well as the brief introduction of their limitations and probably optimal strategies.
